Literature DB >> 20591415

A role for p11 in the antidepressant action of brain-derived neurotrophic factor.

Jennifer L Warner-Schmidt1, Emily Y Chen, Xiaoqun Zhang, John J Marshall, Alexei Morozov, Per Svenningsson, Paul Greengard.   

Abstract

BACKGROUND: The protein p11 (also called S100A10) is downregulated in human and rodent depressive-like states. Considerable experimental evidence also implicates p11 in the mechanism of action of antidepressant drugs and electroconvulsive seizures, in part due to its interaction with specific serotonin receptors. Brain-derived neurotrophic factor (BDNF) has been linked to the therapeutic activity of antidepressants in rodent models and humans. In the current study, we investigated whether BDNF regulates p11 in vitro and in vivo.
METHODS: We utilized primary neuronal cultures, in vivo analyses of transgenic mice, and behavioral techniques to assess the effects of BDNF on p11.
RESULTS: Results indicate that BDNF stimulates p11 expression through tropomyosin-related kinase B (trkB) receptors and via the mitogen-activated protein kinase signaling pathway. Brain-derived neurotrophic factor-induced changes in p11 in vivo correlate with changes in ligand binding to the 5-hydroxytryptamine receptor 1B, the subcellular localization of which is known to be regulated by p11. Behavioral studies demonstrate that p11 knockout mice are insensitive to the antidepressant actions of BDNF.
CONCLUSIONS: Taken together, our data demonstrate that p11 levels are regulated by BDNF in vitro and in vivo and that the antidepressant-like effect of BDNF in two well-established behavioral models requires p11. These data support a role for p11 in the antidepressant activity of neurotrophins. 2010 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20591415      PMCID: PMC2929288          DOI: 10.1016/j.biopsych.2010.04.029

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  38 in total

1.  Sequential activation of the 5-HT1(A) serotonin receptor and TrkB induces the serotonergic neuronal phenotype.

Authors:  D Galter; K Unsicker
Journal:  Mol Cell Neurosci       Date:  2000-05       Impact factor: 4.314

2.  Expression of brain-derived neurotrophic factor in cortical neurons is regulated by striatal target area.

Authors:  J M Canals; N Checa; S Marco; P Akerud; A Michels; E Pérez-Navarro; E Tolosa; E Arenas; J Alberch
Journal:  J Neurosci       Date:  2001-01-01       Impact factor: 6.167

3.  Brain-derived neurotrophic factor and trkB are essential for cAMP-mediated induction of the serotonergic neuronal phenotype.

Authors:  D Galter; K Unsicker
Journal:  J Neurosci Res       Date:  2000-08-01       Impact factor: 4.164

4.  Neurogenic effects of fluoxetine are attenuated in p11 (S100A10) knockout mice.

Authors:  Martin Egeland; Jennifer Warner-Schmidt; Paul Greengard; Per Svenningsson
Journal:  Biol Psychiatry       Date:  2010-03-15       Impact factor: 13.382

5.  Reversal of depressed behaviors in mice by p11 gene therapy in the nucleus accumbens.

Authors:  Brian Alexander; Jennifer Warner-Schmidt; Therese Eriksson; Carol Tamminga; Margarita Arango-Lievano; Margarita Arango-Llievano; Subroto Ghose; Mary Vernov; Mihaela Stavarache; Mihaela Stavarche; Sergei Musatov; Marc Flajolet; Per Svenningsson; Paul Greengard; Michael G Kaplitt
Journal:  Sci Transl Med       Date:  2010-10-20       Impact factor: 17.956

6.  Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus.

Authors:  J E Malberg; A J Eisch; E J Nestler; R S Duman
Journal:  J Neurosci       Date:  2000-12-15       Impact factor: 6.167

7.  Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression.

Authors:  Yukihiko Shirayama; Andrew C-H Chen; Shin Nakagawa; David S Russell; Ronald S Duman
Journal:  J Neurosci       Date:  2002-04-15       Impact factor: 6.167

8.  Increased neurogenesis in a model of electroconvulsive therapy.

Authors:  T M Madsen; A Treschow; J Bengzon; T G Bolwig; O Lindvall; A Tingström
Journal:  Biol Psychiatry       Date:  2000-06-15       Impact factor: 13.382

9.  5-HT2A receptor activation leads to increased BDNF mRNA expression in C6 glioma cells.

Authors:  Robert Meller; Joseph M Babity; David G Grahame-Smith
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

10.  Noradrenergic and serotonergic blockade inhibits BDNF mRNA activation following exercise and antidepressant.

Authors:  A S Ivy; F G Rodriguez; C Garcia; M J Chen; A A Russo-Neustadt
Journal:  Pharmacol Biochem Behav       Date:  2003-04       Impact factor: 3.533

View more
  44 in total

1.  Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans.

Authors:  Jennifer L Warner-Schmidt; Kimberly E Vanover; Emily Y Chen; John J Marshall; Paul Greengard
Journal:  Proc Natl Acad Sci U S A       Date:  2011-04-25       Impact factor: 11.205

2.  The GABAergic deficit hypothesis of major depressive disorder.

Authors:  B Luscher; Q Shen; N Sahir
Journal:  Mol Psychiatry       Date:  2010-11-16       Impact factor: 15.992

Review 3.  Psychiatric drugs bind to classical targets within early exocytotic pathways: therapeutic effects.

Authors:  Henry A Lester; Julie M Miwa; Rahul Srinivasan
Journal:  Biol Psychiatry       Date:  2012-07-06       Impact factor: 13.382

4.  Alteration by p11 of mGluR5 localization regulates depression-like behaviors.

Authors:  K-W Lee; L Westin; J Kim; J C Chang; Y-S Oh; B Amreen; J Gresack; M Flajolet; D Kim; A Aperia; Y Kim; P Greengard
Journal:  Mol Psychiatry       Date:  2015-09-15       Impact factor: 15.992

5.  Ketamine Increases Proliferation of Human iPSC-Derived Neuronal Progenitor Cells via Insulin-Like Growth Factor 2 and Independent of the NMDA Receptor.

Authors:  Alessandra Grossert; Narges Zare Mehrjardi; Sarah J Bailey; Mark A Lindsay; Jürgen Hescheler; Tomo Šarić; Nicole Teusch
Journal:  Cells       Date:  2019-09-24       Impact factor: 6.600

Review 6.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 7.  Pathogenesis of depression: Insights from human and rodent studies.

Authors:  C Ménard; G E Hodes; S J Russo
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

8.  Hippocampal mossy cell involvement in behavioral and neurogenic responses to chronic antidepressant treatment.

Authors:  Seo-Jin Oh; Jia Cheng; Jin-Hyeok Jang; Jeffrey Arace; Minseok Jeong; Chang-Hoon Shin; Jeongrak Park; Junghee Jin; Paul Greengard; Yong-Seok Oh
Journal:  Mol Psychiatry       Date:  2019-03-05       Impact factor: 15.992

9.  Higher BDNF plasma levels are associated with a normalization of memory dysfunctions during an antidepressant treatment.

Authors:  Jan Engelmann; Stefanie Wagner; Daniel Wollschläger; Sabine Kaaden; Konrad F Schlicht; Nadine Dreimüller; Dieter F Braus; Marianne B Müller; Oliver Tüscher; Helge Frieling; André Tadić; Klaus Lieb
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-03-30       Impact factor: 5.270

10.  Early responses to deep brain stimulation in depression are modulated by anti-inflammatory drugs.

Authors:  L Perez-Caballero; R Pérez-Egea; C Romero-Grimaldi; D Puigdemont; J Molet; J-R Caso; J-A Mico; V Pérez; J-C Leza; E Berrocoso
Journal:  Mol Psychiatry       Date:  2013-05-28       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.